Baby product
The US Food and Drug Administration (FDA) provides definitions for all product classes. Briefly, skin care products constitute a broad range of items, including cleansing lotions and creams, depilatories, sprays, moisturizers, and anti-wrinkle products. Personal cleanliness products included bath soaps, deodorants, and douches. Baby products included shampoos, lotions, oils, creams, and powders marketed toward newborns and infants. Hair care products, which include shampoos (noncoloring), rinses (noncoloring), hair spray, and hair straighteners, constituted 35% (n = 1805) of all adverse health reports. Skin care products were the next most common source of complaints at 22% (n = 1148). Five percent of products (n = 257) were not classifiable based on the available data. The data label for each year indicates the total number of adverse events reported. On average, 396 cosmetic-related adverse events were sent to the FDA every year. There was a 78% increase in 2015 and a 300% increase in 2016 for adverse event reports compared with the mean across the entire time period (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) . This increase was largely driven by the hair care products class, specifically the WEN product line by Chaz Dean.
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specifically involving hair care products, compared with the average (Figure 1) . Overall, the 3 most commonly implicated products were hair care (n = 1805), skin care (n = 1148), and tattoos (n = 388). Product classes with significantly higher than average (35.0%) reports of serious health outcomes were as follows: baby (51.8%; 95% CI, 44.2%-59.3%), unclassified (50.2%; 95% CI, 44.1%-56.3%), personal cleanliness (47.1%; 95% CI, 41.2%-53.2%), hair care (43.9%; 95% CI, 41.7%-46.2%), and hair coloring products (40.5%; 95% CI, 35.0%-46.1%) (Figure 2 ). Discussion | Better cosmetic surveillance is needed given their ubiquity and lack of a premarket approval pathway. Unlike devices, pharmaceuticals, and dietary supplements, cosmetic manufacturers have no legal obligation to forward adverse events to the FDA; CFSAN reflects only a small proportion of all events. The data suggest that consumers attribute a significant proportion of serious health outcomes to cosmetics. The lack of high-quality data leads to reactionary responses by the FDA subject to consumer pressure as evidenced by the WEN conditioners controversy. The first step to improve cosmetic safety is broader reporting, especially from manufacturers. Greater coordination with other databases (eg, National Poison Data System) may yield useful collateral information.
There are several limitations to this analysis. Although the FDA removes duplicate reports, there is no causality determination and health outcomes are all self-reported. Demographic information is also limited to sex and age. Additional data on medical comorbidities or concomitant product use would be relevant. Finally, we cannot distinguish reports from consumers vs those from health care professionals.
In 2014, the FDA expressed "profound disappointment" 5 with the industry's draft legislation to modernize cosmetics regulation and refused to invest additional taxpayer dollars for further negotiations. Since then, California's Senator Diane Feinstein has introduced the Personal Care Products Safety Act (PCPSA) 6 with a coalition of supporters. The bill's key components include granting the FDA authority to recall unsafe cosmetics, mandatory manufacturer reporting of adverse events, and a yearly safety review of 5 ingredients. However, the law does not provide more investment to the National Toxicology Program for more rigorous scientific testing. For products blurring the line between drug and cosmetic (cosmeceuticals), a form of premarket approval should be considered. Ultimately, PCPSA is a first step in the right direction to protect consumers. Greater than the mean across all product classes (P <.05) Not significantly different from the mean across all product classes Less than the mean across all product classes (P <.05)
A "serious" adverse health outcome was counted whenever a reporter attributed a specific adverse event with any of the following: serious injury, disability, congenital anomaly, or death. We collapsed 5 product types that had 20 or fewer adverse outcomes, which included bath preparation products, shaving products, cosmetic raw materials, cosmetic devices, and multiple category products into the "other" category. The dashed vertical line illustrates the average percentage of reported adverse events across the 14 product types for each of the adverse health outcomes. An orange dot signifies a higher-than-average percentage compared with the mean (P < .05). A purple dot signifies a lower-than-average percentage compared with the mean (P < .05). A black dot signifies no significant difference compared with the average. Error bars indicate 95% CIs. As expected, products with high percentages of serious adverse events also had lower percentages of nonserious adverse events. question is whether increasing intensity of end-of-life care reflects changes in the extent to which patient preferences are elicited and documented with advance directives. Nursing homes offer an important setting to evaluate advance directive use because they accept full responsibility for care during patient stay.
To shed light on a potentially remediable care gap, we sought to determine whether changes in the use of advance directives between 2000 and 2010 are related to changing patterns of end-of-life care among nursing home residents receiving dialysis.
Methods | We used data from a national registry of patients receiving dialysis linked to Medicare claims and the Minimum Data Set to identify 153 285 nursing home residents who died in 2000 or 2010 with continuous Medicare coverage in the last 6 months of life and a nursing home record between 31 and 365 days before death. The institutional review board at Stanford University and the Veterans Affairs Palo Alto Research Committee approved the study.
We categorized patients according to the presence or absence of 2 advance directive components 1 : a treatmentlimiting advance directive (TLD), defined as documentation of any treatment limitations including resuscitation, hospitalization, feeding, and medications; and a surrogate decision maker. 2 We ascertained 2 outcomes in the last month of life: intensive procedures (resuscitation, intubation, or mechanical ventilation) and intensive care unit (ICU) admission with International Classification of Diseases, Ninth Revision and revenue codes.
We estimated the difference between the change in endof-life care between 2000 and 2010 among patients with 1 or both advance directive components and the change in endof-life care over the same period among patients with neither advance directive component using modified Poisson regression. The models accounted for demographics, clinical characteristics, regional spending, and correlation of patients within nursing homes.
Results | There was little difference in the frequency of TLDs and surrogates in 2000 vs 2010 (Figure) . In both years, 63% of patients had neither advance directive component and fewer than 10% had both. Over the same period, the proportion of patients receiving an intensive procedure in the last month of life increased from 16% to 22% (P < .001) and the proportion admitted to an ICU in the last month of life increased from 34% to 47% (P < .001).
Compared with patients who lacked a TLD and surrogate, the adjusted difference in the proportion of patients receiving an intensive procedure in 2000 vs 2010 did not differ for those with a TLD or surrogate alone, whereas it was 7 percentage points smaller among those with a TLD and surrogate (Table) . There was no difference across these groups in the proportion of patients admitted to the ICU in the last month of life in 2000 vs 2010.
Discussion | The most striking finding from our study of nursing home residents receiving dialysis is the large and persistent gap that exists between what is widely considered standard of care for patients with serious illness-elicitation and documentation of patient goals-and the care that is actually delivered. This gap is noteworthy because advance directives have increased in other segments of the population over the same period. 4, 5 Hospitalization may be the most effective way to care for some chronically ill patients, while for others it is the path of least resistance that leads to an unintended escalation in care. 
